The Pentagon has reinstated mandatory screening for testosterone deficiency among service members age 30 and older after temporarily withdrawing the medical guidance earlier this month for unspecified updates.
By yourNEWS Media Newsroom
WASHINGTON — The Pentagon is moving forward with a military-wide testosterone screening initiative after temporarily halting the program earlier this month, restoring a policy intended to establish standardized testing and treatment procedures for hormone deficiency among service members.
The renewed guidance takes effect immediately and focuses on identifying testosterone deficiency in male personnel age 30 and older, Pentagon spokesperson Sean Parnell said Thursday.
“Effective immediately, this guidance addresses male testosterone deficiency, establishing uniform screening and treatment pathways,” Parnell said.
The announcement ends a brief interruption in a program first unveiled in July by War Secretary Pete Hegseth as part of his broader emphasis on physical conditioning and military readiness.
Hegseth has promoted testing for testosterone deficiency and the medically appropriate use of testosterone as potential tools for maintaining the physical performance of service members as they age.
Under the policy initially announced this summer, service members 30 and older were to undergo mandatory screening.
The original guidance also addressed women, though through a different process. Female service members were expected to complete a questionnaire intended to identify possible hormonal problems and could subsequently undergo evaluation or treatment for hormone-related conditions.
That policy was put on hold in early September.
The Pentagon temporarily rescinded the published medical guidance “to allow for updates,” leaving the future of the initiative uncertain while officials reviewed the requirements.
Thursday’s action restores the testing program.
The Pentagon did not immediately provide a detailed account of what was changed during the pause, making it unclear whether the reinstated policy differs substantially from the version announced in July.
Parnell’s statement specifically described the revived guidance as addressing “male testosterone deficiency.” The Pentagon had not immediately clarified whether the provisions previously announced for female service members had been changed, removed or would be addressed separately.
The initiative represents an unusual military-wide effort to systematically identify low testosterone among personnel beginning at age 30 rather than relying solely on service members presenting symptoms and seeking individual medical evaluation.
Supporters of the initiative have linked hormone health to strength, energy, recovery and physical readiness.
The prospect of widespread screening and treatment has also generated concern among some physicians.
Medical professionals have cautioned that testosterone therapy is not appropriate simply because a laboratory result shows a reduced testosterone level. Diagnosis generally requires consideration of symptoms, medical history and laboratory findings, and unnecessary treatment can expose patients to avoidable risks.
Among the concerns raised about inappropriate testosterone prescribing is reduced fertility because external testosterone can suppress the body’s own reproductive hormone signaling and sperm production.
Other potential health consequences have also prompted physicians to urge careful diagnosis, monitoring and individualized treatment rather than automatic prescribing following a screening result. Reuters reported that some medical professionals have questioned whether widespread military testing is necessary and warned of risks if testosterone is prescribed inappropriately.
The Pentagon’s policy establishes screening and treatment pathways but does not mean that every service member age 30 or older will receive testosterone therapy.
The distinction between screening and treatment is significant because testing can identify personnel who may require additional medical evaluation without automatically determining that medication is warranted.
Hegseth has presented hormone health as one component of his effort to improve military fitness and readiness, placing the initiative alongside broader Pentagon policies emphasizing physical standards.
The temporary withdrawal of the guidance earlier in September raised questions about whether medical or procedural changes were being considered.
Pentagon officials said only that the pause was intended to permit updates.
With the suspension now lifted, mandatory screening is again set to proceed. The department has not publicly detailed what revisions were made between the withdrawal of the earlier guidance and Thursday’s reinstatement.
The program therefore moves into implementation with its central requirement intact: service members age 30 and older will be screened for testosterone deficiency under a standardized Pentagon framework, with further evaluation and treatment available when medically indicated.
Original article
Comments